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Efficacy of mebendazole and levamisole alone or in combination
against intestinal nematode infections after repeated targeted
mebendazole treatment in Zanzibar
M. Albonico,1 Q. Bickle,2 M. Ramsan,3 A. Montresor,4 L. Savioli,4 & M. Taylor2
Objective To evaluate the efficacy of and resistance to mebendazole (500 mg) and levamisole (40 or 80 mg), alone or in combination,
for the treatment of Ascaris lumbricoides, Trichuris trichiura and hookworm infections on Pemba Island — an area exposed to periodic
school-based mebendazole treatment since 1994.
Methods A randomized, placebo-controlled trial was carried out in 914 children enrolled from the first and fifth grades of primary
schools. Stool samples collected at baseline and 21 days after treatment were examined by the Kato–Katz technique to assess the
prevalence and intensity of helminth infection.
Findings Efficacies of mebendazole and levamisole as single treatments against intestinal nematode infections were comparable with
those in previous trials, but mebendazole treatment of hookworm infections gave significantly lower cure (7.6%) and egg reduction
(52.1%) rates than reported in a study undertaken before the beginning of periodic chemotherapy (cure rate, 22.4%; egg reduction
rate, 82.4%). Combined treatment with mebendazole and levamisole had a significantly higher efficacy against hookworm infections
(cure rate, 26.1%; egg reduction rate, 88.7%) than either drug given alone. No difference in mebendazole efficacy was found in
children who had been treated repeatedly compared with those who had not been treated previously.
Conclusion The overall efficacy of mebendazole against hookworm infections after periodic chemotherapy is reduced. The efficacy of
benzimidazoles in chemotherapy-based control programmes should be monitored closely. Combined treatment with mebendazole and
levamisole may be useful as a tool to delay the development of benzimidazole resistance.
Keywords Ascariasis/drug therapy; /Trichuriasis/drug therapy; Ascaris lumbricoides/drug effects; Trichuris/drug effects; Mebendazole/
pharmacology/administration and dosage; Levamisole/pharmacology/administration and dosage; Placebos; Drug therapy,
Combination; Treatment outcome; Ancylostoma/drug effects; Necator americanus/drug effects; Drug resistance; Randomized
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Introduction
Public health programmes to controlmorbidity associatedwith
soil-transmitted helminth infections depend mainly on the
delivery of anthelminthic drugs to primary-school children (1).
In theory, four single-dose drugs are available (albendazole,
levamisole, mebendazole, and pyrantel); in practice, however,
most control programmes only use the benzimidazoles
(albendazole and mebendazole) because they are given as a
single-dose tablet and children do not need to be weighed (2).
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Aside from reducing the load of worms, benzimidazole
treatment also improves the nutritional status and cognitive
development of children infected with Ascaris lumbricoides,
Trichuris trichiura, and hookworms and reduces hookworm-
associated anaemia in children and in women of childbearing
age (3–9). A number of studies have shown the short- and
long-term benefits of periodic treatment with a single dose of
500 mg mebendazole in endemic areas (8, 10, 11).
Levamisole also is used in helminth control programmes
with good results, although it is less effective than mebendazole
against T. trichiura andNecator americanus infections. Comparative
trials of both drugs, alone or in combination, are few, however,
and none have compared single-dose administration of 500 mg
mebendazole and 40 or 80 mg levamisole (12–16).
At present, concern exists about the possible emergence
of drug resistance to the anthelminthic compounds used to
control intestinal nematodes in humans, particularly given the
well-documented and widespread problem of anthelminthic
resistance in livestock as a consequence of frequent periodic
mass treatments (17). The efficacy of combined treatments
that use anthelminthics with differing modes of action (e.g.
mebendazole plus levamisole) need to be assessed, both to
explore possible additive or synergistic effects and to identify a
combination that could delay the occurrence of anthelminthic
drug resistance to each class of drug (18).
Comparison of the efficacy of mebendazole in the
treatment ofA. lumbricoides, T. trichiura, and hookworm infection
in an area where the school-age population has been exposed to
the drug for the last five years with data collected before the
beginning of the control programme andwith other efficacy data
collected elsewhere can give valuable information on possible
changes in drug susceptibility of worms.
The primary purpose of this trial was to evaluate the
efficacy of single-dose mebendazole in an area where this drug
has been used widely for periodic chemotherapy targeted at
schoolchildren. A secondary objective was to assess and
compare the efficacy of mebendazole with that of levamisole
given as one or two 40-mg tablets and the efficacy of the two
drugs given in combination.
Materials and methods
Study area and study population
The study was carried out on Pemba Island, the smaller of the
two islands of Zanzibar, United Republic of Tanzania.
Important features of the island have been described in detail
elsewhere (19, 20). Intestinal helminth infections affect most
of the population and cause a heavy burden of disease in
children and in women of childbearing age (21). The National
HelminthControl Programmewas initiated inZanzibar in June
1994, and since then, mebendazole 500 mg has been given to
schoolchildren as a single dose every 4–6 months (21).
The study was conducted in August 1999 among
children enrolled in the first grade (Standard 1) and fifth grade
(Standard 5) of 10 public schools on Pemba Island. The
schools were chosen randomly from the 72 schools on the
island. Children at Standard 1 had not yet been treated with
mebendazole in school, whereas children at Standard 5 had
been exposed to 15 rounds of mebendazole treatment.
Children were excluded from the trial if they did not have
parental or guardian permission to participate, did not provide
a stool sample, had significant comorbidities (e.g. severe
diarrhoea, severe anaemia, or high fever), or had recently
transferred to the school from an area outside Zanzibar.
Study design
The study was a randomized, placebo-controlled trial. Before
children were enrolled in the study, parents or guardians of
children in the selected schools were given a comprehensive
explanation of the risk and benefits of the trial, and verbal
consent was sought.
Children enrolled in the study were assigned randomly to
one of four treatment groups to receive 500 mg mebendazole
(Janssen, Belgium), 40 or 80 mg levamisole (Zeneca, UK),
500 mg mebendazole plus 40 or 80 mg levamisole, or placebo.
Placebo pills resembled mebendazole in colour, size, taste, and
shape.
On the day before the scheduled treatment date, children
eligible to participate in the trial were given a container in which
to bring a fresh stool sample the next day. On the day of
treatment, the stools were collected and the children’s weights
were recorded. Randomization was blocked on weight, and a
computer-generated programme was used to create two
randomized treatment lists: one for children who weighed
15–20 kg, who were to receive one tablet of 40 mg levamisole,
and another for children who weighed 21–60 kg, who were to
receive two tablets (80mg). One tablet ofmebendazole 500mg
and one of placebo was given irrespective of body weight.
Treatments given were placed in sealed, opaque envelopes and
were coded with a number. Children were identified by these
numbers only throughout the study.
Twenty-one days after treatment, all children were
revisited to collect a further stool sample. Any child who failed
to bring a stool sample was followed for up to 24 days. Parents
and children were instructed to report to the teacher and refer
to the nearest health centre with any severe adverse effects that
occurred in the week after treatment. After completion of the
study, children in the placebo group and children positive after
the follow-up survey were treated with mebendazole 500 mg.
The study was approved by the Zanzibar Health
Research Council, and by the ethical committees of WHO
and the London School of Hygiene and Tropical Medicine.
Parasitology
After both surveys, egg counts in stool samples were assessed
within sixhoursof the samplebeingproducedat thePublicHealth
Laboratory Ivo de Carneri. All laboratory investigations were
blinded, so the technicianswhoexamined the slideswereunaware
of the treatment the patients received. Stools were analysed using
theKato–Katz techniqueaccording toWHOguidelines (22).The
slides were examined within one hour of preparation to avoid
overclarification of hookworm eggs. Comparison of egg counts
before and after treatment allowed calculation of the cure rate and
the egg reduction rate. A random sample of 10% of the smears
prepared for the Kato–Katz technique was read by two different
technicians to evaluate the accuracy of the diagnosis and the
precision of the egg counts. Slides were re-examined if the quality
control showed a >10% difference in egg counts.
To describe the egg count distribution in the study
population before and after treatment, intensity of infection
was classified as ‘‘light’’, ‘‘moderate’’, or ‘‘heavy’’ on the basis of
faecal egg counts. As no heavy infections with A. lumbricoides
were present at baselinewhen analysed according toWHOcut-
off points, categories for A. lumbricoides intensity of moderate
and heavy infection were revised to include a meaningful
number of children for comparison (Table 1). Categories for
intensity of T. trichiura and hookworm infection are according
to WHO guidelines (Table 1) (23).
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Statistical analysis
Data were entered and analysed with EpiInfo software. Cure
rates were calculated as the percentage of children with egg
counts >0 before treatment who had negative egg counts after
treatment. The percentage reduction in prevalence was
calculated as [(N+/n) – (N21
+/n)]/(N+/n), where N+ = the
number of positive children at baseline, N21
+ = the number of
positive children 21 days after treatment, and n = the total
number of children with samples from both day 0 and day 21.
Both cure rates and percentage reductions in prevalence were
calculated. As the sensitivity of the Kato–Katz method could
be influenced by the intensity of infection, however, reductions
in prevalence were comparable only when pre-treatment
intensities of infection were similar.
The percentage reduction in eggs induced by treatment
was estimated as 100[1 – exp(–D)]%], whereD = S (loge(E21)
– loge(E0))/n, E21 = the egg count at 21 days (for each
individual), E0 = the count before treatment, and n = the
number of children. Confidence intervals were based on the
inter-individual variation in the differences in the logarithms of
the egg counts. Proportions were compared with standard
w2 tests. Geometric mean egg counts were estimated as
exp[S(loge(c+1))/n] – 1, where c = the count (eggs per gram)
for a particular individual and n= the total number of samples.
Geometric means were compared with analyses of variance by
ANOVA if Bartlett’s test of heterogenicity indicated homo-
geneity of variances and by the Kruskal–Wallis test if Bartlett’s
test was significant at the 5% level.
Results
Analysis of baseline data
Of 1137 children examined at the baseline, 904 (79.5%)
returned stool samples at follow-up. Loss at follow-up was
high compared with that in other surveys in Pembian
schoolchildren because of an unexpected closure of schools
on Pemba Island one week before the scheduled 21-day
follow-up. The schools were closed for three weeks to allow
children to help harvest an unusually large crop of cloves. The
research staff thus walked from hut to hut through each village
to trace missing children. Subsequent analysis showed that
older, male children were more likely to be lost to follow-up,
presumably because of their increased involvement in clove
picking (12.2 vs 11.6 years, P<0.001; 54.5% boys vs 47.0%
girls, P<0.05) (Table 2). Children subsequently lost at follow-
up had similar baseline prevalence and intensity of A. lum-
bricoides, T. trichiura, and hookworm infections to children who
were followed up.
Results are presented on the cohort of 904 children who
returned a stool sample for the baseline and post-treatment
surveys (Table 3). Their mean (SD; range) age was 11.5 (2.4; 7–
18) years, and 45% were boys. The four groups were
homogeneous at baseline for age and helminth infections,
but differed in the proportion of males to females (Table 2).
The prevalence of any helminth infection was 99.7%, with
38.3% and 54.9% of children harbouring double and triple
infections, respectively. Table 3 gives the prevalence and
intensity of A. lumbricoides, T. trichiura, and hookworms at
baseline and 21 days after treatment in the four treatment
groups.
Overall drug efficacy
Follow-up egg counts, cure rates, reductions in prevalence and
egg reduction rates for the three nematode infections were
statistically significantly better with all of the drug regimens
compared with those at baseline, except for cure rates for
hookworm infections with mebendazole and for T. trichiura
infections with levamisole (although in both cases the mean
egg counts were reduced substantially). Compared with
placebo, all drug treatments produced significantly higher cure
rates and egg reduction rates and lower prevalences at follow-
up, except for the egg reduction rate for levamisole in
T. trichiura infections (Table 3).
Both drugs had very high efficacy (98.5% and 99.1% egg
reduction rates for levamisole and mebendazole, respectively)
against A. lumbricoides. Mebendazole alone and in combination
with levamisole had better efficacy than levamisole alone for
T. trichiura infection (81% and 85% vs 41.5% egg reduction
rates, P<0.001). Levamisole treatment produced a marginally
significant reduction in prevalence of hookworm infection,
which was greater than the reduction seen with mebendazole
(8.9% vs 3.6%, P<0.05); the combination had better efficacy in
reducing prevalence than either drug alone (23.6%, P<0.001).
The egg reduction rate for hookworm infection was 88.7% for
the combined treatment, but significantly less for either drug
alone (61.3% for levamisole and 52.1% for mebendazole,
P<0.001).
Figure 1 shows the distribution of intensities of
infections, expressed as eggs per gram faeces, before and after
treatment for A. lumbricoides, T. trichiura, and hookworm
infections. Higher efficacy of treatment is indicated by an
increase in negative and light infections and a decrease in
moderate and heavy infections 21 days after treatment.
Stratified analysis by intensity was performed on the cure rates
and egg reduction rates for each species of helminth. For any
treatment, lower cure rates were achieved in children with
heavy infections compared with light infections:A. lumbricoides
93.3% vs 97.0% (P=0.07), T. trichiura 8.3% vs 19.3% (P=0.1),
and hookworm 8.4% vs 16.3% (P<0.05). On the other hand,
higher egg reduction rates were achieved in childrenwith heavy
compared with light infections for T. trichiura (93.8% vs 81.4%,
P<0.05) and hookworm (91.3% vs 73.2%, P<0.01). Efficacy
of treatment was not influenced by whether A. lumbricoides,
T. trichiura, or hookworm infections presented as single or
multiple infections. Although adverse effects were not
investigated actively, no adverse events were reported after
any single or combined treatment in the week following the
administration of anthelminthics.
Drug efficacy in Standard 1 and Standard 5 children
Overall, 446 childrenwere in Standard 1 classes and had amean
(SD) age of 9.5 (1.5) years, and 458 children were in Standard
Table 1. Egg counts (eggs per gram) used to describe intensity
of infection
Causative pathogen Intensity of infection
(egg count per gram)
Light Moderate Heavy
A. lumbricoides 1–4999 5000–9999 510 000
T. trichiura 1–999 1000–9999 510 000
Hookworm 1–1999 2000–3999 5 4000
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5 classes and had a mean (SD) age of 13.4 (1.3) years. Boys
accounted for 49.8% and 40.4% of children from Standard 1
and Standard 5 classes, respectively. Tables 4 and 5 give the
prevalences and intensities of A. lumbricoides, T. trichiura, and
hookworm infections at baseline and 21 days after treatment in
the four treatment groups in Standard 1 and Standard 5
children, respectively. The baseline mean intensities of
infection for all three species of helminths were significantly
higher in the Standard 1 children than in the Standard 5
children (P<0.001). In addition, Standard 1 children at baseline
had higher prevalences of moderate and heavy infection for
each helminth than Standard 5 children — (A. lumbricoides:
moderate 14.1% vs 9.2%, heavy 18.8% vs 9.0%; T. trichiura:
moderate 45.3% vs 22.3%, heavy 2.5% vs 0.2%; and
hookworm: moderate 12.1% vs 6.3%, heavy 11.4% vs 5.0%).
In both Standard 1 and Standard 5 children, but
particularly in Standard 1 children, mebendazole and its
combination with levamisole were more effective than
levamisole in T. trichiura infection (the efficacy of levamisole
did not differ significantly from that of placebo). In Standard 1
Table 2. Characteristics of the study sample at baseline
Characteristic Treatment
Mebendazole Levamisole Mebendazole + levamisole Placebo
Total Lost at follow-up Total Lost at follow-up Total Lost at follow-up Total Lost at follow-up
(n = 285) (n = 49) (n = 277) (n = 67) (n = 286) (n = 70) (n = 289) (n = 47)
Mean age (years ) 11.5 (2.3)a 12.3 (2.1) 11.7 (2.5) 12.1(2.3) 11.7 (2.4) 12.2 (2.5) 11.6 (2.5) 12.1 (2.3)
Sex (% boys) 48.4 53.1 54.2 56.7 43.0 55.7 42.6 51.1
Ascaris
Prevalence (%) 61.4 69.4 60.3 62.7 62.9 65.7 58.1 63.8
Geometric mean (epg)b 134 292 99 117 129 149 100 122
Trichuris
Prevalence (%) 90.9 91.8 94.6 97.0 93.7 95.7 93.8 93.6
Geometric mean (epg) 304 315 365 384 371 421 458 346
Hookworm
Prevalence (%) 95.1 95.9 96.0 95.5 95.1 98.6 95.2 89.4
Geometric mean (epg) 429 352 454 392 401 504 475 316
a Values in parentheses are standard deviations.
b epg = eggs per gram.
Table 3. Results before and 21 days after treatment with mebendazole, levamisole, mebendazole + levamisole, and placebo
Causative Prevalencea Egg count (epg)b
pathogen Drug n Day 0 Day 21 Day 0 Day 21 Cure Reduction P-valuec Egg reduction P-valuec
rate in prevalence rate
Ascaris Mebendazole 236 59.7 3.0 114 0.2 96.5 95.0 <0.001 99.0 (98.2–99.4)d <0.001
Levamisole 210 59.5 5.7 94 0.4 91.2 90.4e <0.001 98.5 (97.4–99.1) <0.001
Mebendazole + levamisole 216 62.0 1.4 131 0.1 98.5 97.7 <0.001 99.1 (98.4–99.5) <0.001
Placebo 242 57.0 51.2 96 63 22.5 10.2 NSf 33.9 (0.4–56.1) NS
Total 904 59.5 106
Trichuris Mebendazole 236 90.7 75.0 302 57 22.9 17.3g <0.001 81.0 (71.9–87.1)g <0.001
Levamisole 210 93.8 90.0 359 210 9.6 4.1h NS 41.5 (17.8–58.4)h <0.01
Mebendazole + levamisole 216 93.1 74.5 356 53 22.9 20.0 <0.001 85.0 (78.5–89.5) <0.001
Placebo 242 93.8 94.2 484 395 4.8 –0.4 NS 18.3 (–7.0–37.6 ) NS
Total 904 92.8 371
Hookworms Mebendazole 236 94.9 91.5 447 213 7.6 3.6h,i NS 52.1 (36.0–64.2)h <0.001
Levamisole 210 96.2 87.6 476 184 11.9 8.9h <0.001 61.3 (47.2–71.6)h <0.001
Mebendazole + levamisole 216 94.0 71.8 373 41 26.1 23.6 <0.001 88.7 (83.9–92.0) <0.001
Placebo 242 96.3 95.9 514 432 3.4 0.4 NS 16.0 (–8.0–34.6) NS
Total 904 95.4 451
a Percentage positive for pathogen.
b Mean egg count expressed as geometric mean.
c P-value from day 21 to day 0.
d Values in parentheses are 95% confidence intervals.
e Compared with mebendazole plus levamisole P<0.05.
f NS, not significant.
g Compared with levamisole P<0.001.
h Compared with mebendazole plus levamisole P<0.001.
i Compared with levamisole P<0.05.
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children, the effect of mebendazole against hookworm
infection was similar to that of placebo, although its reduction
of intensity of infection approached statistical significance (egg
reduction rate 37%, P = 0.06), while levamisole was more
effective (egg reduction rate 66.3%, P<0.001) and the
combination was the best treatment (egg reduction rate
92.9%, P<0.001). In Standard 5 children, the combination was
still the better option (although to a lesser extent than in
Standard 1 children) than either drug alone for the treatment of
hookworm infection (egg reduction rate 81.9% vs 56.3% for
levamisole and 60.4% for mebendazole, P<0.05). Overall,
none of cure rate, percentage reduction in prevalence, or egg
reduction rate differed significantly between Standard 1 and
Standard 5 children for any helminth infection. Furthermore,
no evidence was seen of a reduced cure or egg reduction rate
for mebendazole relative to levamisole in Standard 5 children
compared with Standard 1 children.
Discussion
This study confirms the extremely high prevalence of intestinal
nematode infections in Zanzibar despite the periodic che-
motherapy control programme that started in 1994. The
objective of this programme, however, was reduction in
intensity rather than prevalence of infection. In this respect, the
significantly lower egg counts at baseline in Standard 5 children
who had received 15 rounds of treatment with mebendazole
compared with children in Standard 1 classes, who had never
been treated, are encouraging. A possible explanation for this
finding could be an intrinsic decline in intensity with increasing
age. This is not supported by a previous study on untreated
children in the same population, however, which showed that
between the ages of 9 (Standard 1) and 13 years (Standard 5),
the mean intensity of ascariasis in fact increased, the intensity
of hookworm infections remained stable, and the intensity of
trichuriasis slightly decreased, although to a much lesser extent
than between Standard 1 and Standard 5 children in the present
study (21). The benefit of periodic chemotherapy is shown
further in the significant reduction of moderate and heavy
helminth infections — those most associated with morbidity
— in Standard 5 children. From the public health perspective,
it seems, therefore, that the helminth control programme is
effective in reducing intensity, although the low efficacy of
treatment of hookworm infections found in this trial is
worrying.
High, and similar, levels of efficacy in the treatment of
A. lumbricoides infection were achieved using mebendazole,
levamisole, and their combination. The efficacy of each
treatment was equally excellent in light and heavyA. lumbricoides
infections, with egg reduction rates approaching 100%. This
result is consistent with previous efficacy trials and is also
similar — for mebendazole — to the results of an efficacy
study carried out in Pemba in 1993 before the mebendazole-
based control programme was started (14, 24–27).
Drug efficacies inT. trichiura infectionwere also similar to
those seen in previous trials, as treatment with mebendazole
reduced the prevalence of infection, while levamisole had a
much smaller effect (14, 26–29). Reductions in egg counts
were significant for mebendazole and for levamisole, although
mebendazole and the combined treatment were both
significantly better than levamisole alone. When compared
with the efficacy trial performed in Pemba before the control
programme started, the mebendazole cure and egg reduction
Table 4. Results before and 21 days after treatment with mebendazole, levamisole, mebendazole + levamisole, and placebo
in Standard 1 children
Causative Prevalencea Egg count (epg)b
pathogen Drug n Day 0 Day 21 Day 0 Day 21 Cure Reduction P-valuec Egg reduction P-valuec
rate in prevalence rate
Ascaris Mebendazole 120 67.5 5.8 264 0.4 93.8 91.4d <0.001 99.5 (98.8–99.7)e <0.001
Levamisole 98 70.4 4.1 254 0.4 94.2 94.2f <0.001 99.5 (98.8–99.8) <0.001
Mebendazole + levamisole 108 67.6 0.1 248 0.1 100.0 99.9 <0.001 99.6 (99.1–99.8) <0.001
Placebo 120 65.0 61.7 192 152 17.9 5.1 NSg 20.9 (–44.1–56.6) NS
Total 446 67.5 237
Trichuris Mebendazole 120 95.0 76.7 534 69 22.8 19.3h <0.001 86.9 (78.0–92.2)h <0.001
Levamisole 98 95.9 95.9 643 416 4.2 0d NS 35.2 (–3.7–59.5)d NS
Mebendazole + levamisole 108 97.0 82.4 776 94 17.1 15.1 <0.001 87.9 (80.6–92.4) <0.001
Placebo 120 95.0 95.8 726 590 4.4 –0.8 NS 18.8 (–18.8–44.5) NS
Total 446 95.7 661
Hookworms Mebendazole 120 94.1 95.0 483 304 4.4 –1.0i NS 37.0 (6.0–57.8)d,i 0.06
Levamisole 98 99.0 90.8 827 278 9.2 8.3d <0.01 66.3 (48.7–7.8)d <0.001
Mebendazole + levamisole 108 96.3 71.3 604 42 26.0 26.0 <0.001 92.9 (88.7–95.6) <0.001
Placebo 120 96.7 98.3 674 619 0.9 –1.7 NS 8.1 (–29.0–34.6) NS
Total 446 96.4 628.0
a Percentage positive for pathogen.
b Mean egg count expressed as geometric mean.
c P-value from day 21 to day 0.
d Compared with mebendazole plus levamisole P<0.01.
e Values in parentheses are 95% confidence intervals.
f Compared with mebendazole plus levamisole P<0.05.
g NS, not significant.
h Compared with levamisole P<0.001.
i Compared with levamisole P<0.05.
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rates were not significantly different (24). The poor efficacy of
levamisole against T. trichiura has already been reported,
although Ismail et al. showed an egg reduction rate of 73% (2,
14). The finding that egg reduction rates were significantly
higher in both T. trichiura and hookworm ‘‘heavy’’ infections
compared with ‘‘light’’ infections is consistent with trials with
albendazole (29, 30).
Striking features of this study were the low cure (7.6%)
and egg reduction (52.1%) rates when mebendazole was used
against hookworms. Mebendazole efficacy was lower when
compared with that in published studies and, more specifically,
compared with that in the trial carried out in Pemba before
exposure to periodic treatment, in which mebendazole had a
cure rate of 22.4% and an egg reduction rate of 82.4% (14, 24–
27). Furthermore, in a recent trial comparable with our trial in
the neighbouring island of Mafia, in which there is no school-
based deworming programme and use of benzimidazoles has
been very limited, mebendazole efficacies were similar (cure
rate 31.3%; egg reduction rate 78.1%) to the pre-treatment
values on Pemba and very much higher than the current
efficacy in Pemba (31).
A number of potential confounding factors were ruled
out by the fact that both trials were carried out in school-
children by the same staff and used the samemethods and drug
(mebendazole 500mg from Janssen). It is notable that the cure
rates and egg reduction rates for Ascaris and Trichuris were
comparable between the two trials. Interestingly, levamisole
also showed a lower efficacy against hookworms in the present
study than in previous studies (32–34). A possible explanation
is that levamisole has been reported to be more effective
againstA. duodenale thanN. americanus, but the latter pathogen is
the most prevalent species in Pemba (20). If mebendazole also
was less effective against N. americanus, repeated use of
mebendazole in Pemba could have created an increased
Necator:Ancylostoma ratio, which would have resulted in an
overall lower efficacy against hookworms. Data from recent
studies suggest that the Necator:Ancylostoma ratio is indeed
higher now than it was before periodic anthelminthic treatment
(Albonico, unpublished data, 2000) (20).
An alternative explanation for the apparent reduced
efficacy of mebendazole compared with historical controls is
the selection of drug resistance by the repeated treatment
regimen. If a proportion of drug-resistant worms was present
in the worm population in Pemba, we would have expected
resistant worms to have accumulated in children after multiple
rounds of treatment and reinfection and to have represented a
higher proportion of worms than that found in Standard 1
children. In this case, a lower drug efficacy would have been
expected in the Standard 5 children. In fact, the efficacy of
mebendazole in Standard 5 children who had receivedmultiple
(15) doses of mebendazole was not lower than in Standard 1
children who had never been treated; this suggests that a
mebendazole-resistant population of worms had not accumu-
lated in the repeatedly treated Standard 5 children. Never-
theless, the possibility that drug resistance is emerging in
Pemba cannot be excluded. In Mali, failure of mebendazole in
the treatment of human hookworm infections has been
reported (35). In that case, however, the population had not
been exposed to periodic treatment with mebendazole,
although mebendazole had been available in that community
for some years; pre-exposure efficacy data were not available
for comparison and the sample of children studied was rather
small. These factors suggest a need for caution when
interpreting these results. A subsequent drug efficacy study
in Mali (36) showed reasonably good efficacy of mebendazole
and even better results from albendazole, which show a lack of
significant resistance in human hookworms to benzimidazoles
in that area. Poor efficacy of pyrantel against hookworms has
Table 5. Results before and 21 days after treatment with mebendazole, levamisole, mebendazole + levamisole, and placebo
in Standard 5 children
Causative Prevalencea Egg count (epg)b
pathogen Drug n Day 0 Day 21 Day 0 Day 21 Cure Reduction P-valuec Egg reduction P-valuec
rate in prevalence rate
Ascaris Mebendazole 116 51.7 0.1 47 0.1 100.0 99.8d <0.001 97.9 (95.8–99.0) <0.0001
Levamisole 112 50.9 7.1 39 0.5 87.5 86.1e <0.001 96.1 (92.0–98.1) <0.0001
Mebendazole + levamisole 108 56.5 2.8 61 0.2 96.7 95.0 <0.001 98.0 (95.7–99.1) <0.0001
Placebo 122 49.2 41.0 48 26 28.3 16.7 NS 44.5 (3.8–68.0) NS
Total 458 51.7 48
Trichuris Mebendazole 116 86.2 73.3 167 46 23.0 15.0 <0.01 72.1 (51.1–84.1) <0.001
Levamisole 112 92.0 84.8 215 115 14.6 7.8f NS 46.5 (12.6–67.2)e <0.05
Mebendazole + levamisole 108 88.9 66.6 163 30 29.2 25.1 <0.001 81.4 (68.0–89.1) <0.001
Placebo 122 92.6 92.6 325 266 5.3 0.0 NS 17.8 (–19.0–43.2) NS
Total 458 90.0 211
Hookworms Mebendazole 116 95.7 87.9 412 148 10.8 8.2e <0.05 60.4 (45.2–76.4)e <0.001
Levamisole 112 93.7 84.8 293 128 14.3 9.5e <0.05 56.3 (30.7–72.4)e <0.01
Mebendazole + levamisole 108 91.7 72.2 230 41 25.3 21.3 <0.001 81.9 (70.1–89.0) <0.001
Placebo 122 95.9 93.4 395 304 6.0 2.6 NS 23.0 (–11.5–46.8) NS
Total 458 94.3 327
a Percentage positive for pathogen.
b Mean egg count expressed as geometric mean.
c P-value from day 21 to day 0.
d Compared with levamisole P<0.001.
e Compared with mebendazole plus levamisole P<0.05.
f Compared with mebendazole plus levamisole P<0.001.
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been found in north-west Australia, but again it is not known if
this represents a decline in efficacy because of emerging
resistance (37).
The efficacy of the combined administration of
mebendazole 500 mg and levamisole 40 or 80 mg was
evaluated for the first time in this study and showed higher
efficacy than either drug alone against hookworm infections.
This is a promising result, because the combined administra-
tion of two different anthelminthic drugs could be used as the
treatment of choice in this context. In addition, the adoption of
combination therapy with drugs with distinct modes of action
when used at early stages has been shown to delay the onset of
anthelminthic drug resistance (18).
Although this study clearly shows that the efficacy of
mebendazole in the treatment of hookworm infections in
Pemba Island schoolchildren is lower than in previous studies,
demonstration of anthelminthic resistance is still lacking. A
need exists, therefore, for alternative methods by which to
address this question, such as the in vitro egg hatch assay — a
technique widely used in veterinary medicine (38) and recently
adapted to human hookworms (39). This would require
comparisons with strains of hookworms that had not been
exposed to treatment. The early detection of drug resistance is
of the utmost importance, because the in vivo and in vitro tests
currently available in the veterinary field detect resistance when
the proportion of worms carrying the drug resistance allele in a
population already has reached >25% (40). The development
of methods for the early detection of benzimidazole resistance
in human nematodes would be of great value, therefore, and
the polymerase chain reaction methods developed by
veterinary scientists need to be evaluated for their applicability
in human nematodes (41). n
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Re´sume´
Efficacite´ du me´bendazole et du le´vamisole seuls ou en association contre les ne´matodoses intestinales
apre`s traitement pe´riodique cible´ par le me´bendazole a` Zanzibar
Objectif Evaluer l’efficacite´ du me´bendazole (500 mg) et du
le´vamisole (40 ou 80 mg) et la re´sistance a` ces compose´s administre´s
seuls ou en association pour le traitement des infections a` Ascaris
lumbricoides, Trichuris trichiura et les ankylostomes sur l’ıˆle de
Pemba, une re´gion ou` sont effectue´s depuis 1994 des traitements
pe´riodiques par le me´bendazole en milieu scolaire.
Me´thodes Un essai controˆle´ randomise´ contre placebo a e´te´
re´alise´ sur 914 enfants des premier et cinquie`me niveaux de
l’enseignement primaire. Des e´chantillons de selles recueillis au
de´but de l’e´tude et 21 jours apre`s le traitement ont e´te´ examine´s
par la technique de Kato-Katz afin d’e´valuer la pre´valence et
l’intensite´ des helminthiases.
Re´sultats L’efficacite´ du me´bendazole et du le´vamisole en
traitement unique des ne´matodoses intestinales e´tait comparable
a` celle observe´e lors de pre´ce´dents essais, mais le traitement des
ankylostomiases par le me´bendazole donnait des taux de gue´rison
(7,6 %) et de re´duction du nombre d’œufs (52,1 %) significative-
ment plus faibles que lors d’une e´tude re´alise´e avant le de´but de la
chimiothe´rapie pe´riodique (taux de gue´rison : 22,4 % ; taux de
re´duction du nombre d’œufs : 82,4 %). Le traitement associe´ par le
me´bendazole et le le´vamisole e´tait significativement plus efficace
contre les ankylostomiases (taux de gue´rison : 26,1 % ; taux de
re´duction du nombre d’œufs : 88,7 %) qu’un traitement par
chacun des me´dicaments administre´s se´pare´ment. Aucune
diffe´rence d’efficacite´ du me´bendazole n’a e´te´ observe´e entre les
enfants ayant rec¸u une chimiothe´rapie pe´riodique et ceux qui
n’avaient jamais e´te´ traite´s auparavant.
Conclusion Il semble d’apre`s les re´sultats que l’efficacite´ globale
du me´bendazole contre les ankylostomiases apre`s chimiothe´rapie
pe´riodique soit diminue´e. L’efficacite´ des benzimidazole´s dans le
cadre des programmes de lutte reposant sur la chimiothe´rapie doit
eˆtre e´troitement surveille´e. Un traitement associant le me´benda-
zole et le le´vamisole peut eˆtre utile pour retarder le de´veloppement
de la re´sistance a` cette cate´gorie de me´dicaments.
Resumen
Eficacia del mebendazol y el levamisol, solos o combinados, contra las infecciones intestinales
por nematodos despue´s del tratamiento repetido focalizado con mebendazol en Zanzı´bar
Objetivo Evaluar la eficacia del mebendazol (500 mg) y el
levamisol (40 u 80 mg), solos o combinados, y la resistencia a ellos
como tratamiento de las infecciones por Ascaris lumbricoides y
Trichuris trichiura y de la anquilostomiasis en la Isla de Pemba, una
zona en la que desde 1994 se llevan a cabo perio´dicamente
tratamientos con mebendazol en las escuelas.
Me´todos Se llevo´ a cabo un ensayo aleatorizado y controlado
mediante placebo en 914 nin˜os inscritos en alguno de los cinco
primeros an˜os de escuela primaria. Las muestras de heces
obtenidas en la situacio´n de partida y a los 21 dı´as de tratamiento
fueron analizadas mediante la te´cnica de Kato-Katz a fin de evaluar
la prevalencia y la intensidad de las infecciones por helmintos.
Resultados La eficacia del mebendazol y el levamisol como
tratamientos u´nicos de las infecciones intestinales por
nematodos fue comparable a la observada en ensayos
anteriores, pero la administracio´n de mebendazol contra las
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infecciones por anquilostoma logro´ unas tasas de curacio´n
(7,6%) y de reduccio´n del nu´mero de huevos (52,1%)
significativamente inferiores a las notificadas en un estudio
emprendido antes del comienzo de la antibioticoterapia
perio´dica (tasa de curacio´n, 22,4%; tasa de reduccio´n del
nu´mero de huevos, 82,4%). El tratamiento combinado con
mebendazol y levamisol tuvo una eficacia significativamente
mayor contra las infecciones por anquilostoma (tasa de
curacio´n, 26,1%; tasa de reduccio´n del nu´mero de huevos,
88,7%) que cualquiera de los medicamentos por separado. No
se observo´ ninguna diferencia en cuanto a la eficacia del
mebendazol entre los nin˜os tratados repetidamente y los que
no habı´an sido tratados anteriormente.
Conclusio´n La eficacia global del mebendazol contra la
anquilostomiasis se ve reducida despue´s de la antibioticoterapia
perio´dica. Deberı´a vigilarse estrechamente la eficacia de los
benzimidazoles en los programas de control basados en la
antibioticoterapia. El tratamiento combinado con mebendazol y
levamisol podrı´a ser una valiosa arma para retrasar la aparicio´n de
resistencia a los benzimidazoles.
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